AHU377

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

HypertensionSystolic Hypertension

Phase 2

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

CompletedNCT00549770

Novartis PharmaceuticalsHypertension

Start: 2007-09-30End: 2008-07-31Updated: 2015-08-25

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

CompletedNCT01281306

Novartis PharmaceuticalsSystolic Hypertension

Start: 2011-01-31End: 2011-12-31Updated: 2016-01-29

Related Papers

LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.

2015-09-0428 citations

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

2010-03-16439 citations